Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ferric derisomaltose - Pharmacosmos

Drug Profile

Ferric derisomaltose - Pharmacosmos

Alternative Names: Diafer; Iron isomaltoside 1000; Iron oligosaccharide; Isofer; Jilazo; Monofar; Monofer; MONOFERRIC; Monoferric; Monover; NS 32

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmacosmos
  • Developer Cosmopharm; Nippon Shinyaku; Pfizer; Pharmacosmos
  • Class Antianaemics; Disaccharides; Ferric compounds
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Iron deficiency anaemia
  • Phase III Metabolic disorders; Postpartum haemorrhage

Most Recent Events

  • 17 Mar 2023 Launched for Iron deficiency anaemia in Japan prior to March 2023 (IV)
  • 28 Nov 2022 Phase-III clinical trials in Iron deficiency anaemia (In adolescents, In children, In infants, In neonates) in USA (IV) (NCT05179226)
  • 28 Oct 2022 University of Glasgow completes a IRONMAN trial for ferric derisomaltose in iron deficiency anaemia (NCT02642562)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top